OneWorld Health Sends Delegates To The UK To Discuss The Control And Treatment Of Diarrheal Diseases In The Developing World

Main Category: GastroIntestinal / Gastroenterology
Also Included In: Infectious Diseases / Bacteria / Viruses;  Aid / Disasters;  Conferences
Article Date: 08 Oct 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The Institute for OneWorld Health (iOWH), the US-based non-profit pharmaceutical company that develops drugs for people with infectious diseases in the developing world, announced that a delegation of US experts in diarrheal disease is meeting in the UK from October 6-9, 2008. The meeting, organized by the British Consulate General in San Francisco, will include specialists from the UK government, such as the Department for International Development, research organizations and funding bodies. They will meet with the US delegation to discuss the problems of diarrheal disease around the world and explore potential joint initiatives and collaborations to combat the problem. Diarrheal diseases kill approximately two million children under the age of five in developing countries each year, which is more than the combined pediatric death toll due to AIDS, tuberculosis and malaria.

Julie Cheng, Esq, and David Brown, Ph.D., will be attending on behalf of the Institute for OneWorld Health. Ms. Cheng, General Counsel and VP Business Development for iOWH, oversees all of One World Health's legal matters and is responsible for business development, setting up key partnerships among OneWorld Health, academia and pharmaceutical companies in different disease areas. Dr. Brown is a Senior Advisor and Head of OneWorld Health's drug discovery program and has over 30 years experience in the pharmaceutical industry, both in research and in senior executive roles.

OneWorld Health's diarrheal disease program is currently focused on developing an anti-secretory drug that will help alleviate dehydration due to diarrheal disease, and is supported by Roche and funded by the Bill and Melinda Gates Foundation. "This is a great opportunity for stakeholders in both the US and the UK to collaborate and attack one of the leading causes of death for the world's children." says James Hickman, Vice President of External Affairs for OneWorld Health.

About the Institute for OneWorld Health

The Institute for OneWorld Health, the first US nonprofit pharmaceutical company, develops safe, effective and affordable medicines for people with neglected diseases of the developing world. The Institute for OneWorld Health, headquartered in San Francisco, California, USA, is a tax-exempt 501 (c) (3) US corporation. (http://www.oneworldhealth.org/).

Institute for OneWorld Health